Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recent Financings of Private Companies (02/2011)

This article was originally published in Start Up

Executive Summary

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.

You may also be interested in...



New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add three new products, including Velsipity, Pfizer's treatment for moderately to severely active ulcerative colitis in patients 16 years of age and older.

Haleon Surprises Analysts With Stand-Out Cold & Flu Showing In Q4

In describing Haleon’s Q4 showing as a “strong finish to the year,” Bernstein’s Bruno Monteyne pointed to “remarkable strength in respiratory health,” with the category resoundingly beating analysts’ consensus estimates of a 2.5% decline.

As Vyvgart Surges To Blockbuster Status, Argenx Maps Out Expansion Plans

The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC092075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel